Embarrassment or lack of understanding may prevent patients from raising their hands for help1,2

YOU CAN START THE CONVERSATION TODAY

Many patients may not raise their hands for help because they do not realize that primary axillary hyperhidrosis is a treatable medical condition1

Dr. Adam Friedman talks about how he initiates a conversation about primary axillary hyperhidrosis with a sufferer
Despite the fact that hyperhidrosis may be life-altering,78% of sufferers reported feeling less confident than they would like to be,65% of sufferers reported feeling moderately to extremely limited at work, 71% of sufferers reported feeling unhappy or depressed
Despite the fact that hyperhidrosis may be life-altering...
  • 78% of sufferers reported feeling less confident than they would like to be3*

  • 65% of sufferers reported feeling moderately to extremely limited at work3

  • 71% of sufferers reported feeling unhappy or depressed3
Many patients don’t bring it up with their healthcare providers
Many patients don’t bring it up with their healthcare providers
  • Approximately 70% of the 10 million Americans with primary axillary hyperhidrosis remain undiagnosed and untreated1

  • Despite the embarrassment and low self-confidence sufferers feel, approximately 50% have never discussed their excessive sweating with a healthcare professional1,2

ENCOURAGE YOUR PATIENTS TO START THE CONVERSATION TODAY

Raise awareness of primary axillary hyperhidrosis within your practice
Raise awareness of primary axillary hyperhidrosis within your practice
  • Integrate sweat assessment question(s) into your patient intake process

    – Allows your patients to share their condition in a non-embarrassing way

  • Use social media to help get the word out about primary axillary hyperhidrosis and QBREXZA

    – Go to QBREXZA.com/HCP to download an e-media kit

  • Highlight on your website that excessive underarm sweating is a condition you treat in your practice
Educate your patients that primary axillary hyperhidrosis is a treatable medical condition that affects approximately 10 million Americans
Educate your patients that primary axillary hyperhidrosis is a treatable medical condition that affects approximately 10 million Americans1
  • People with hyperhidrosis produce 4 to 5 times more sweat than average4

  • Hyperhidrosis may not be life-threatening, but it is life-altering. Many patients report feeling3:

    – Less confident than they would like to be

    – Moderately to extremely limited at work

    – Unhappy or depressed

QBREXZA is the first and only prescription medicated cloth towelette5
  • Targets the sweat glands to reduce excessive underarm sweating

Several ideas on how you can proactively approach the conversation
Several ideas on how you can proactively approach the conversation
  • Appointment objective: “We have discussed your [reason for visit] – do you have anything else you would like to talk about, like excessive underarm sweating?”

  • Fact-based: “Did you know millions of Americans like you suffer from excessive underarm sweating? Would you like to learn more about the condition and how we may be able to treat it?”

  • Observation: “I noticed you are sweating today, is this a problem for you?”

Shawn, diagnosed in 2016, QBREXZA clinical trial patient Meet Shawn

“I knew [my sweating] wasn't normal, but it wasn't something I really wanted to talk about”

Shawn, diagnosed in 2016, QBREXZA clinical trial patient Meet Shawn
Kristen, diagnosed in 2009, QBREXZA patient

“The more you can explain to the patient [about primary axillary hyperhidrosis]...I think that really helps comfort the patient”

Kristen, diagnosed in 2009, QBREXZA patient Meet Kristen

*Versus 3% of control patients.3

†Versus 1% of control patients.3

‡Versus 0% of control patients.3

References:

  1. Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308:743-749.
  2. Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients’ daily life and quality of life: a qualitative investigation. Health Qual Life Outcomes. 2017;15:121.
  3. Hamm H, Naumann MK, Kowalski JW, Kütt S, Kozma C, Teale C. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology. 2006;212:343-353.
  4. Defining hyperhidrosis. International Hyperhidrosis Society. https://www.sweathelp.org/home/defining-hyperhidrosis.html. Accessed February 13, 2019.
  5. QBREXZA™ (glycopyrronium) cloth prescribing information, Dermira.
INDICATION

QBREXZA is an anticholinergic indicated for topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older.

IMPORTANT SAFETY INFORMATION

Contraindications: QBREXZA is contraindicated in patients with medical conditions that can be exacerbated by the anticholinergic effect of QBREXZA (e.g., glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis, Sjogren’s syndrome).

WARNINGS AND PRECAUTIONS

Worsening of Urinary Retention: QBREXZA should be used with caution in patients with a history or presence of documented urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, distended bladder), especially in patients with prostatic hypertrophy or bladder-neck obstruction. Instruct patients to discontinue use immediately and consult a physician should any of these signs or symptoms develop. Patients with a history of urinary retention were not included in the clinical studies.

Control of Body Temperature: In the presence of high ambient temperature, heat illness (hyperpyrexia and heat stroke due to decreased sweating) can occur with the use of anticholinergic drugs such as QBREXZA. Advise patients using QBREXZA to watch for generalized lack of sweating when in hot or very warm environmental temperatures and to avoid use if not sweating under these conditions.

Operating Machinery or an Automobile: Transient blurred vision may occur with use of QBREXZA. If blurred vision occurs, the patient should discontinue use until symptoms resolve. Patients should be warned not to engage in activities that require clear vision such as operating a motor vehicle or other machinery, or performing hazardous work until the symptoms have resolved.

ADVERSE REACTIONS

The most common adverse reactions seen in ≥2% of subjects treated with QBREXZA were dry mouth (24.2%), mydriasis (6.8%), oropharyngeal pain (5.7%), headache (5.0%), urinary hesitation (3.5%), vision blurred (3.5%), nasal dryness (2.6%), dry throat (2.6%), dry eye (2.4%), dry skin (2.2%) and constipation (2.0%). Local skin reactions, including erythema (17.0%), burning/stinging (14.1%) and pruritus (8.1%) were also common.

DRUG INTERACTIONS

Anticholinergics: Coadministration of QBREXZA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects. Avoid coadministration of QBREXZA with other anticholinergic-containing drugs.

INSTRUCTIONS FOR ADMINISTERING QBREXZA

Instruct patients to use one cloth to apply QBREXZA to both axillae by wiping the cloth across one underarm, ONE TIME. Using the same cloth, apply the medication to the other underarm, ONE TIME. Inform patients that QBREXZA can cause temporary dilation of the pupils and blurred vision if it comes in contact with the eyes.

Instruct patients to wash their hands with soap and water immediately after discarding the used cloth.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no available data on QBREXZA use in pregnant women to inform a drug-associated risk for adverse developmental outcomes.

Lactation: There are no data on the presence of glycopyrrolate or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for QBREXZA and any potential adverse effects on the breastfed infant from QBREXZA or from the underlying maternal condition.

Renal Impairment: The elimination of glycopyrronium is severely impaired in patients with renal failure.

Please see Full Prescribing Information.